Metex Pen

Methotrexate, the active ingredient in Metex Pen, is an antimetabolite presented as a pre‑filled pen for subcutaneous injection use. It treats rheumatoid arthritis, psoriasis, psoriatic arthritis and Crohn's disease in adult patients by modulating immune activity and reducing inflammation and improving quality of life.

GNH USA supplies Metex Pen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet global healthcare demands through reliable logistics and dedicated customer support.

Methotrexate is an antimetabolite used to manage immune‑mediated inflammatory diseases. - Rheumatoid arthritis: reduces joint inflammation and pain, slows radiographic progression, and improves functional ability in adult patients. - Psoriasis: diminishes formation of thickened skin plaques, reduces erythema and scaling, leading to clearer skin and better quality of life. - Psoriatic arthritis: alleviates joint pain and swelling, prevents further joint damage, and improves accompanying skin lesions. - Crohn's disease: helps induce and maintain remission by suppressing intestinal immune activity, reducing ulceration and abdominal symptoms.

Methotrexate may cause a range of adverse reactions, from mild to severe, that require monitoring.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: persistent tiredness or reduced energy levels. - Headache: occasional cranial discomfort. - Elevated liver enzymes: mild increase detected in routine blood tests.

Serious or Rare Side Effects: - Bone marrow suppression: risk of anemia, leukopenia, or thrombocytopenia. - Severe liver toxicity: potential for hepatitis, fibrosis or cirrhosis. - Pulmonary toxicity: interstitial pneumonitis or pulmonary fibrosis.

When prescribing methotrexate, clinicians should observe several safety measures. - Pregnancy contraindication: avoid use in pregnancy (Category X) due to teratogenic risk. - Renal function: assess kidney function before initiation and monitor regularly. - Hepatic monitoring: perform baseline and periodic liver function tests. - Concomitant NSAIDs: use with caution as they may increase toxicity. - Alcohol consumption: limit intake to reduce liver injury risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may cause severe infection; avoid concurrent use. - Trimethoprim‑sulfamethoxazole: can increase risk of bone marrow suppression. - Proton pump inhibitors (high dose): may reduce renal clearance, increasing toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may raise methotrexate levels. - Azathioprine: additive immunosuppression may increase infection risk. - Penicillamine: can enhance methotrexate toxicity.